Embolx Earns CE Mark for Sniper Microcatheters

Silicon Valley-based Embolx earned a CE Mark for its next generation Sniper balloon occlusion microcatheters for the treatment of cancerous tumors, enlarged prostate and uterine fibroids.

The microcatheters are available in 110 cm, 130 cm and 150 cm lengths, enabling physicians to access through femoral or radial arterial sites.

The microcatheters increase therapeutic agent delivery to target areas, while protecting surrounding healthy tissues, by controlling pressure to alter blood flow. Advancements in the balloon and tip designs allow larger vessels to be occluded and improve the ability to track inside vessels.

The Sniper devices received 510(k) clearance from the FDA in June.